US20060147507A1 - Hot flash treatment system - Google Patents
Hot flash treatment system Download PDFInfo
- Publication number
- US20060147507A1 US20060147507A1 US11/325,043 US32504306A US2006147507A1 US 20060147507 A1 US20060147507 A1 US 20060147507A1 US 32504306 A US32504306 A US 32504306A US 2006147507 A1 US2006147507 A1 US 2006147507A1
- Authority
- US
- United States
- Prior art keywords
- solution
- topical
- hot
- topical solution
- treatment system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000033830 Hot Flashes Diseases 0.000 title claims abstract description 48
- 206010060800 Hot flush Diseases 0.000 title claims abstract description 48
- 238000011282 treatment Methods 0.000 title claims description 18
- 238000000034 method Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 6
- 244000186892 Aloe vera Species 0.000 claims abstract description 6
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 6
- 229940100613 topical solution Drugs 0.000 claims description 23
- 208000024891 symptom Diseases 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims description 2
- 229940043234 carbomer-940 Drugs 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- -1 Diazolidinyl Chemical group 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 20
- 239000000499 gel Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000009245 menopause Effects 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002657 hormone replacement therapy Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 208000006001 Hypothalamic Neoplasms Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 229940092980 adalat Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960005092 calcitonin (human synthetic) Drugs 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229940063628 catapres Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229940101566 miacalcin Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940089949 procardia Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940072335 vancocin Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention is directed to topical treatments for reducing the symptoms of perimenopausal, menopausal and postmenopausal hot flashes.
- a hot flash is characterized by a sudden, intense, hot feeling on the face and upper body, perhaps preceded or accompanied by a rapid heartbeat and sweating, nausea, dizziness, anxiety, headache, weakness, or a feeling of suffocation.
- Some women experience an “aura,” an uneasy feeling just before the hot flash, that lets them know what's coming.
- the flash is followed by a flush, leaving one reddened and perspiring.
- the intensity of the flash determines whether the individual becomes soaked in perspiration or merely suffers a moist upper lip. A chill can lead off the episode or be the finale.
- hot flashes occur during the night, they can cause sleeplessness (insomnia), resulting in poor concentration, memory problems, irritability and exhaustion during the day.
- hot flashes are due to a menopause-related drop in the body's level of female hormones called estrogens. This drop affects the hypothalamus, an area of the brain that regulates body temperature. In a hot flash, the hypothalamus seems to sense that the body is too hot even when it is not, and tells the body to release the excess heat.
- the heart pumps faster, the blood vessels in the skin dilate, particularly those near the skin of the head, face, neck and chest, to circulate more blood to radiate off the heat, and the sweat glands release sweat to cool the body off even more. Once the blood vessels return to normal size, the person feels cool again.
- This heat-releasing mechanism is how the body keeps from overheating in the summer, but when a drop in estrogen triggers the process instead, the brain's confused response can make a person very uncomfortable.
- Some women's skin temperature can rise six degrees Centigrade during a hot flash. The body cools down when it shouldn't, and the person is uncomfortable: soaking wet in the middle of a board meeting or in the middle of a good night's sleep.
- Hot flashes affect about 85% of women during the years immediately before and after menopause. Menopause usually occurs around age 51, but hot flashes can begin as early as 2 to 3 years before the last menstrual period. Hot flashes can last for 6 months to as long as 15 years after the final period. The average is two years. Some women have only a few episodes a year, while others have as many as 20 episodes a day.
- Hot flashes occur in women who experience natural menopause, as well as in women who undergo menopause because their ovaries have been removed surgically or because they take medications that lower estrogen levels. These medications include gonadotropin-releasing hormone agonists, such as leuprolide (Lupron) or danazol (Danocrine) that lower estrogen levels. Women that have had breast cancer have hot flashes that can follow the same pattern as for women in general, or they can be more intense and last longer, particularly if menopause was premature, or if you are taking tamoxifen and your body hasn't adjusted to it.
- gonadotropin-releasing hormone agonists such as leuprolide (Lupron) or danazol (Danocrine) that lower estrogen levels.
- Women that have had breast cancer have hot flashes that can follow the same pattern as for women in general, or they can be more intense and last longer, particularly if menopause was premature, or if you are taking tamoxifen and your body hasn't
- hot flashes usually are considered a female problem
- men can have hot flashes if their levels of the male sex hormone testosterone drop suddenly and dramatically.
- hot flashes occur in 75% of men with prostate cancer who have surgery to remove the testes (orchiectomy) or who take medication to decrease testosterone levels.
- symptoms that mimic hot flashes can occur in both men and women who have a tumor of the hypothalamus or pituitary gland, certain serious infections such as tuberculosis or HIV, alcoholism or thyroid disorders.
- Symptoms that are similar to hot flashes also can be a side effect of the food additive monosodium glutamate (MSG), or of certain medications, particularly nitroglycerin (sold under many brand names), nifedipine (Procardia, Adalat), niacin (numerous brand names), vancomycin (Vancocin) and calcitonin (Calcimar, Cibacalcin, Miacalcin).
- HRT Hormone Replacement Therapy
- Alternative medications to help decrease the intensity of hot flashes include clonidine (Catapres), lofexidine (Britlofex), methyldopa (Aldomet), or antidepressants such as venlafaxine (Effexor), paroxetine (Paxil), fluoxetine (Prozac) and sertraline (Zoloft).
- the present invention includes a topical solution and or a disposable cloth containing a topical solution for the treatment of perimenopausal, menopausal and postmenopausal hot flash symptoms.
- the topical solution is applied to certain parts of the body, which cools the body and relieves the symptoms associated with a hot flash. Reducing the body's temperature or deceiving the body into believing that it is cooler reduces the severity of the hot flash.
- a method of alleviating the symptoms of menopausal hot flashes in a human comprising selecting a subject in need of treatment for hot flashes; and applying an amount of solution to certain parts of the subject's body, wherein the solution effectively cools the subject's body is disclosed.
- a topical solution for treating the symptoms associated with a hot flash comprising an alcohol and an aloe vera gel is disclosed.
- a treatment for the symptoms of a hot flash comprising a topical solution; a container for storing and or dispensing said topical solution is disclosed.
- the invention provides a composition comprising an aloe vera gel and an alcohol.
- the composition can be formulated to provide quick and sustained release of the active ingredients after administration to a patient by employing procedures known in the art.
- the topical solution is non-hormonal and or non-prescription and is applied in liquid, lotion, gel or other equally suitable form.
- the topical solution may also be applied via a disposable piece of paper or cloth such as a towelette impregnated with the topical solution or in a roll-on form.
- topical solution to their arms, neck and or other parts of their body.
- the topical solution is applied to the back of both arms, starting at the wrists, and to the back of the neck.
- Application of the topical solution to the user's body parts simulates rinsing in cool water, and therefore reduces the heat sensations normally felt during a “hot flash”.
- the topical solution may be dispensed from a variety of different containers including, but not limited to, bottles, tubes, pop-up wipe plastic tubs, foil or plastic pouches, individual tearable pouches, and the like.
- small individual containers that are appropriate for carrying in a pocket or purse are contemplated.
- the composition includes one or more of an Aloe Vera Gel, Alcohol, Triethanolamine, Tocopheryl acetate, Carbomer 940, Tetrasodium EDTA, DMDM Hydantoin and Diazolidinyl urea.
- the alcohol is an Isopropyl Alcohol.
- the composition may include one or more of the following optional additives such as colorants, perfumes, etc.
- each of these additives should be both miscible and compatible with the other ingredients of the composition.
- Compatible additives are those that do not prevent the use of the composition in the manner prescribed herein.
- the composition may be administered in a therapeutically effective amount. It will be understood that the amount of the composition actually administered may be determined by the individual in light of the relevant circumstances, including the severity of the condition to be treated, the chosen route of administration, the actual composition administered and the age, weight and response of the individual, and the like.
- the composition is applied to the skin surface of the patient at the desired site.
- the composition may be applied to the face, scalp, neck, trunk, back, limbs, axillae, and/or groin of the individual.
- the composition is applied to the back of each arm beginning at the wrists and to the back of the neck. It has been found that the application of the composition to the skin of humans suffering from hot flashes reduces or eliminates the symptoms thereof.
- Topical compositions may be in the form of a solution, cream, ointment, mousse, gel, lotion, powder or aerosol formulation adapted for application to the skin.
- Topical compositions containing the compounds of the present invention preferably include from about 50% to 70% by weight aloe vera gel and preferably include from about 20% to 30% by weight an alcohol, although other combinations and percentages of ingredients are contemplated and are believed to perform suitably.
- Topical preparation containing the active compound can be admixed with a variety of carrier materials or pharmaceutically acceptable excipients well known in the art.
- the excipient serves as a dilutent, it can be a solid, semi-solid, or liquid, which acts as a vehicle, carrier or medium for the active ingredient.
- the compositions can be in the form of powders, suspensions, emulsions, solutions, syrups, alcoholic solutions, ointments, topical cleansers, cleansing creams, skin gels, skin lotions, mousses, roll-ons, aerosol or non-aerosol sprays in cream or gel formulations and soft gelatin capsules.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A composition comprising an alcohol and an aloe vera gel for topically treating hot flashes and methods for the storing, dispensing and application thereof.
Description
- This application claims priority under 35 U.S.C. 119 of U.S. provisional application Ser. No. 60/641,231 filed Jan. 4, 2004, the contents of which are fully incorporated herein by reference.
- The present invention is directed to topical treatments for reducing the symptoms of perimenopausal, menopausal and postmenopausal hot flashes.
- A hot flash is characterized by a sudden, intense, hot feeling on the face and upper body, perhaps preceded or accompanied by a rapid heartbeat and sweating, nausea, dizziness, anxiety, headache, weakness, or a feeling of suffocation. Some women experience an “aura,” an uneasy feeling just before the hot flash, that lets them know what's coming.
- The flash is followed by a flush, leaving one reddened and perspiring. The intensity of the flash determines whether the individual becomes soaked in perspiration or merely suffers a moist upper lip. A chill can lead off the episode or be the finale. When hot flashes occur during the night, they can cause sleeplessness (insomnia), resulting in poor concentration, memory problems, irritability and exhaustion during the day.
- Researchers do not know exactly what causes hot flashes. Current theories suggest hot flashes are due to a menopause-related drop in the body's level of female hormones called estrogens. This drop affects the hypothalamus, an area of the brain that regulates body temperature. In a hot flash, the hypothalamus seems to sense that the body is too hot even when it is not, and tells the body to release the excess heat. The heart pumps faster, the blood vessels in the skin dilate, particularly those near the skin of the head, face, neck and chest, to circulate more blood to radiate off the heat, and the sweat glands release sweat to cool the body off even more. Once the blood vessels return to normal size, the person feels cool again.
- This heat-releasing mechanism is how the body keeps from overheating in the summer, but when a drop in estrogen triggers the process instead, the brain's confused response can make a person very uncomfortable. Some women's skin temperature can rise six degrees Centigrade during a hot flash. The body cools down when it shouldn't, and the person is miserable: soaking wet in the middle of a board meeting or in the middle of a good night's sleep.
- Hot flashes affect about 85% of women during the years immediately before and after menopause. Menopause usually occurs around age 51, but hot flashes can begin as early as 2 to 3 years before the last menstrual period. Hot flashes can last for 6 months to as long as 15 years after the final period. The average is two years. Some women have only a few episodes a year, while others have as many as 20 episodes a day.
- There is considerable variation in time of onset, duration, frequency, and the nature of hot flashes, whether an individual has had breast cancer or not. An episode can last a few seconds or a few minutes, occasionally even an hour, but it can take another half hour for someone to feel them self again. The most common time of onset is between six and eight in the morning, and between six to ten at night.
- Hot flashes occur in women who experience natural menopause, as well as in women who undergo menopause because their ovaries have been removed surgically or because they take medications that lower estrogen levels. These medications include gonadotropin-releasing hormone agonists, such as leuprolide (Lupron) or danazol (Danocrine) that lower estrogen levels. Women that have had breast cancer have hot flashes that can follow the same pattern as for women in general, or they can be more intense and last longer, particularly if menopause was premature, or if you are taking tamoxifen and your body hasn't adjusted to it.
- Although hot flashes usually are considered a female problem, men can have hot flashes if their levels of the male sex hormone testosterone drop suddenly and dramatically. For example, hot flashes occur in 75% of men with prostate cancer who have surgery to remove the testes (orchiectomy) or who take medication to decrease testosterone levels.
- In addition, symptoms that mimic hot flashes can occur in both men and women who have a tumor of the hypothalamus or pituitary gland, certain serious infections such as tuberculosis or HIV, alcoholism or thyroid disorders. Symptoms that are similar to hot flashes also can be a side effect of the food additive monosodium glutamate (MSG), or of certain medications, particularly nitroglycerin (sold under many brand names), nifedipine (Procardia, Adalat), niacin (numerous brand names), vancomycin (Vancocin) and calcitonin (Calcimar, Cibacalcin, Miacalcin).
- Currently, Hormone Replacement Therapy (“HRT”), or the taking of estrogen alone or in combination with progesterone or other hormones, is believed to be one of the most effective treatments available to reduce the onset of hot flashes. These hormones can be taken as a pill, injected, administered through a skin patch and or applied in a cream. For example, for women who have undergone surgical menopause and have unusually severe hot flashes, some studies have shown that a combination of estrogen and androgen may be effective. Alternative medications to help decrease the intensity of hot flashes include clonidine (Catapres), lofexidine (Britlofex), methyldopa (Aldomet), or antidepressants such as venlafaxine (Effexor), paroxetine (Paxil), fluoxetine (Prozac) and sertraline (Zoloft).
- In addition to HRT and other medications, several nonprescription dietary supplements or herbal remedies are promoted as natural ways to prevent or treat hot flashes. Several studies in humans suggest that black cohosh, red clover and soy may be safe and effective for improving symptoms of menopause. There are several other known suggested hot flash remedies such as changing one's wardrobe, becoming physically active, reducing intake of triggering foods and beverages and relaxation that are aimed at preventing or reducing the number of hot flashes experienced.
- Certain drawbacks exist with current treatments for hot flashes. Because of potential side effects and dangers of hormone therapy, as outlined in several medical studies, many women choose not to use HRT in any form. Also, because other medications or dietary supplements are often ineffective or can cause undesired effects, many women choose to forgo these treatments as well.
- Even when effective, however, the above-mentioned remedies are geared at reducing the onset of a hot flash rather than treating the symptoms or relieving the discomfort of an ongoing hot flash. Therefore, when a hot flash occurs, these treatments do little if anything to reduce the intense hot feeling on the face and upper body, rapid heartbeat, sweating, nausea, dizziness, anxiety, headache, weakness or a feeling of suffocation.
- Presently there are no known hot flash treatments that include a topical solution for the safe, simple and immediate treatment of hot flash symptoms. Accordingly, a need exists for such a remedy.
- It is therefore an object of the present to provide a non-hormonal and or non-prescription remedy for the safe, simple and immediate treatment of hot flash symptoms
- The present invention includes a topical solution and or a disposable cloth containing a topical solution for the treatment of perimenopausal, menopausal and postmenopausal hot flash symptoms.
- The topical solution is applied to certain parts of the body, which cools the body and relieves the symptoms associated with a hot flash. Reducing the body's temperature or deceiving the body into believing that it is cooler reduces the severity of the hot flash.
- Other objects will, in part, be obvious and will, in part, appear hereinafter. The invention accordingly, comprises the features of construction, combination of elements and arrangements of parts, which will be exemplified in the following detailed description and the scope of the invention will be indicated in the claims.
- According to one aspect of the invention, a method of alleviating the symptoms of menopausal hot flashes in a human, comprising selecting a subject in need of treatment for hot flashes; and applying an amount of solution to certain parts of the subject's body, wherein the solution effectively cools the subject's body is disclosed.
- As to another aspect of the invention, a topical solution for treating the symptoms associated with a hot flash, comprising an alcohol and an aloe vera gel is disclosed.
- As to yet another aspect of the invention, a treatment for the symptoms of a hot flash comprising a topical solution; a container for storing and or dispensing said topical solution is disclosed.
- For purpose of illustration, and not to limit generally, the present invention will now be described with specific reference to certain embodiments. In a first aspect, the invention provides a composition comprising an aloe vera gel and an alcohol. The composition can be formulated to provide quick and sustained release of the active ingredients after administration to a patient by employing procedures known in the art.
- In certain embodiments of the present invention the topical solution is non-hormonal and or non-prescription and is applied in liquid, lotion, gel or other equally suitable form. The topical solution may also be applied via a disposable piece of paper or cloth such as a towelette impregnated with the topical solution or in a roll-on form.
- To treat the symptoms of a hot flash a user applies the topical solution to their arms, neck and or other parts of their body. In a preferred embodiment, the topical solution is applied to the back of both arms, starting at the wrists, and to the back of the neck. Application of the topical solution to the user's body parts simulates rinsing in cool water, and therefore reduces the heat sensations normally felt during a “hot flash”.
- The topical solution may be dispensed from a variety of different containers including, but not limited to, bottles, tubes, pop-up wipe plastic tubs, foil or plastic pouches, individual tearable pouches, and the like. In certain embodiments, small individual containers that are appropriate for carrying in a pocket or purse are contemplated.
- In a certain embodiment the composition includes one or more of an Aloe Vera Gel, Alcohol, Triethanolamine, Tocopheryl acetate, Carbomer 940, Tetrasodium EDTA, DMDM Hydantoin and Diazolidinyl urea. In certain embodiments the alcohol is an Isopropyl Alcohol.
- The composition may include one or more of the following optional additives such as colorants, perfumes, etc. In practice, each of these additives should be both miscible and compatible with the other ingredients of the composition. Compatible additives are those that do not prevent the use of the composition in the manner prescribed herein.
- The composition may be administered in a therapeutically effective amount. It will be understood that the amount of the composition actually administered may be determined by the individual in light of the relevant circumstances, including the severity of the condition to be treated, the chosen route of administration, the actual composition administered and the age, weight and response of the individual, and the like.
- The composition is applied to the skin surface of the patient at the desired site. The composition may be applied to the face, scalp, neck, trunk, back, limbs, axillae, and/or groin of the individual. Preferably, the composition is applied to the back of each arm beginning at the wrists and to the back of the neck. It has been found that the application of the composition to the skin of humans suffering from hot flashes reduces or eliminates the symptoms thereof.
- The compounds of the present invention may be administered in a composition comprising the active compounds in combination with an acceptable carrier adapted for topical administration. Topical compositions may be in the form of a solution, cream, ointment, mousse, gel, lotion, powder or aerosol formulation adapted for application to the skin. These topical compositions containing the compounds of the present invention preferably include from about 50% to 70% by weight aloe vera gel and preferably include from about 20% to 30% by weight an alcohol, although other combinations and percentages of ingredients are contemplated and are believed to perform suitably.
- Topical preparation containing the active compound can be admixed with a variety of carrier materials or pharmaceutically acceptable excipients well known in the art. When the excipient serves as a dilutent, it can be a solid, semi-solid, or liquid, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of powders, suspensions, emulsions, solutions, syrups, alcoholic solutions, ointments, topical cleansers, cleansing creams, skin gels, skin lotions, mousses, roll-ons, aerosol or non-aerosol sprays in cream or gel formulations and soft gelatin capsules.
- Having thus described multiple illustrative embodiments of the invention, various alterations, modifications and improvements will readily occur to those skilled in the art. Such alterations, modifications and improvements are intended to be within the scope and spirit of the invention. Accordingly, the foregoing description is by way of example only and is not intended as limiting. The invention's limit is defined only in the following claims and the equivalents thereto.
Claims (16)
1. A method of alleviating the symptoms of menopausal hot flashes in a human, comprising:
a. selecting a subject in need of treatment for hot flashes; and
b. applying an amount of solution to certain parts of the subject's body, wherein the solution effectively cools the subject's body.
2. The method of claim 1 wherein the solution is applied to the back of the subject's neck and arms.
3. The method of claim 1 wherein the solution is in the form of a lotion.
4. The method of claim 1 wherein the solution is in the form of a gel.
5. The method of claim 1 wherein the solution is in the form of a roll-on.
6. The method of claim 1 wherein the solution is in the form of a cream.
7. The method of claim 1 wherein the solution is in the form of a towelette impregnated with a lotion.
8. A topical solution for treating the symptoms associated with a hot flash, comprising an alcohol and an aloe vera gel.
9. The topical solution of claim 8 wherein the topical solution further includes one or more of the group of ingredients comprising Triethanolamine, Carbomer 940, DMDH Hydanton, Diazolidinyl, Tetra-sodium EDTA and Tocopheryl Acetate.
10. The topical solution of claim 8 wherein the alcohol is an isopropyl alcohol.
11. The topical solution of claim 8 further comprising a fragrance.
12. A treatment for the symptoms of a hot flash comprising:
a. a topical solution containing an alcohol and aloe vera; and
b. a container for storing and or dispensing said topical solution.
13. The treatment system of claim 12 wherein the container includes a roll-on applicator.
14. The treatment system of claim 12 wherein the container is a portable tearable pouch.
15. The treatment system of claim 12 wherein the topical solution is in the form of a gel.
16. The treatment system of claim 12 further comprising a towelette impregnated with the topical solution for the application thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/325,043 US20060147507A1 (en) | 2005-01-04 | 2006-01-04 | Hot flash treatment system |
| US11/974,111 US8216194B2 (en) | 2005-01-04 | 2007-10-11 | Hot flash treatment system |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64123105P | 2005-01-04 | 2005-01-04 | |
| US11/325,043 US20060147507A1 (en) | 2005-01-04 | 2006-01-04 | Hot flash treatment system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/974,111 Continuation US8216194B2 (en) | 2005-01-04 | 2007-10-11 | Hot flash treatment system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20060147507A1 true US20060147507A1 (en) | 2006-07-06 |
Family
ID=36640698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/325,043 Abandoned US20060147507A1 (en) | 2005-01-04 | 2006-01-04 | Hot flash treatment system |
| US11/974,111 Expired - Fee Related US8216194B2 (en) | 2005-01-04 | 2007-10-11 | Hot flash treatment system |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/974,111 Expired - Fee Related US8216194B2 (en) | 2005-01-04 | 2007-10-11 | Hot flash treatment system |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20060147507A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070193278A1 (en) * | 2006-02-16 | 2007-08-23 | Polacek Denise C | Cooling device and method |
| US20080311166A1 (en) * | 2007-06-14 | 2008-12-18 | Wimer Allan H | Cooling towel |
| US20090110656A1 (en) * | 2007-10-31 | 2009-04-30 | Lemke Sarah A | Skin cooling composition |
| US20090157153A1 (en) * | 2007-12-13 | 2009-06-18 | Sarah Anne Lemke | Skin cooling system |
| US20110123595A1 (en) * | 2009-05-17 | 2011-05-26 | Gnr Sports Innovations, Llc | Personal Stimulating Wiping Systems |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8053004B2 (en) * | 2007-10-08 | 2011-11-08 | Starmaker Products, Llc | Ointment for topical treatment of hot flashes and method of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962505A (en) * | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
| US20030176904A1 (en) * | 2002-03-15 | 2003-09-18 | Ardella Patterson | Cold strip wrist band |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2915529A (en) | 1957-04-15 | 1959-12-01 | Jefferson Chem Co Inc | Method for preparing glycerin carbonate |
| US3637774A (en) | 1969-11-03 | 1972-01-25 | Vigen K Babayan | Process for preparation and purification of polyglycerols and esters thereof |
| US5646190A (en) * | 1991-03-01 | 1997-07-08 | Warner-Lambert Company | Acne treating-wound healing compositions and methods for preparing and using same |
| WO1995016723A1 (en) | 1993-12-14 | 1995-06-22 | Unichema Chemie B.V. | Polyglycerol production |
| FR2733232B1 (en) | 1995-04-24 | 1997-06-13 | Organisation Nationale Interpr | PROCESS FOR THE MANUFACTURE OF GLYCEROL CARBONATE FROM GLYCEROL AND AN ORGANIC CYCLIC CARBONATE, IN PARTICULAR ETHYLENE OR PROPYLENE CARBONATE |
| US6645506B1 (en) * | 1997-04-18 | 2003-11-11 | Ganeden Biotech, Inc. | Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil |
| FR2778182B1 (en) | 1998-04-30 | 2000-07-21 | Organisation Nationale Interpr | PROCESS FOR THE MANUFACTURE OF GLYCEROL CARBONATE |
| US6558710B1 (en) * | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
| US20040185115A1 (en) * | 2002-05-17 | 2004-09-23 | Maurine Pearson | Emu oil based methods and compositions for skin ailments |
| US20040185088A1 (en) * | 2002-05-17 | 2004-09-23 | Maurine Pearson | Emu oil based methods and compositions for elastomeric devices |
| WO2004050023A2 (en) * | 2002-11-27 | 2004-06-17 | Dmi Biosciences, Inc. | Treatment of diseases and conditions mediated by increased phosphorylation |
-
2006
- 2006-01-04 US US11/325,043 patent/US20060147507A1/en not_active Abandoned
-
2007
- 2007-10-11 US US11/974,111 patent/US8216194B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962505A (en) * | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
| US20030176904A1 (en) * | 2002-03-15 | 2003-09-18 | Ardella Patterson | Cold strip wrist band |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070193278A1 (en) * | 2006-02-16 | 2007-08-23 | Polacek Denise C | Cooling device and method |
| US20080311166A1 (en) * | 2007-06-14 | 2008-12-18 | Wimer Allan H | Cooling towel |
| US20090110656A1 (en) * | 2007-10-31 | 2009-04-30 | Lemke Sarah A | Skin cooling composition |
| US20090157153A1 (en) * | 2007-12-13 | 2009-06-18 | Sarah Anne Lemke | Skin cooling system |
| US20110123595A1 (en) * | 2009-05-17 | 2011-05-26 | Gnr Sports Innovations, Llc | Personal Stimulating Wiping Systems |
| US8337882B2 (en) | 2009-05-17 | 2012-12-25 | David Garrow | Personal stimulating wiping systems |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080033376A1 (en) | 2008-02-07 |
| US8216194B2 (en) | 2012-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8512718B2 (en) | Pharmaceutical composition for topical application | |
| US6967023B1 (en) | Pharmaceutical and cosmetic carrier or composition for topical application | |
| US6060070A (en) | Isoflavonoids for treatment and prevention of aging skin and wrinkles | |
| KR100950524B1 (en) | Topical Glycopyrrolate Products | |
| US8216194B2 (en) | Hot flash treatment system | |
| JP2000319187A (en) | Carbon dioxide transcutaneous and transmucosal absorption composition | |
| JP2011088930A (en) | Carbon dioxide percutaneous and transmucosal absorption composition | |
| JP2005082600A (en) | How to treat skin symptoms | |
| JPH1059829A (en) | Hair tonic | |
| CN105770237A (en) | Foaming agent with itching-relieving and inflammation-diminishing effects and preparation method of foaming agent | |
| US20250143905A1 (en) | Topical treatment for anorectal disorders with and without seat cushion | |
| US8053004B2 (en) | Ointment for topical treatment of hot flashes and method of use | |
| JP5699184B2 (en) | Carbon dioxide transdermal / mucosal absorption composition | |
| SCHRIOCK et al. | Treatment of hirsutism | |
| JP2007262083A (en) | Carbon dioxide percutaneous/transmucosal absorption composition | |
| JP3113705B2 (en) | External preparation | |
| JP3027838B2 (en) | Eyazole composition | |
| JP2024516652A (en) | Topical preparations containing benzoyl peroxide and azelaic acid and uses thereof | |
| WO2016029015A1 (en) | Transdermal pharmaceutical compositions including testosterone and an aromatase inhibitor | |
| CN110269926A (en) | Middle benefit gas, which is relaxed, warms up composition and its preparation method and application | |
| JPH0517202B2 (en) | ||
| Bilovol et al. | Cosmetology: textbook for the 2nd-year dentistry students (English medium) | |
| JP2013177461A (en) | Composition for percutaneously and transmucosally absorbing carbon dioxide | |
| JP2013166779A (en) | Composition for carbon dioxide percutaneous-transmucosal absorption | |
| WO2024012386A1 (en) | Composition containing artemisia annua l. extract and oil-soluble component, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: FLASH BE GONE HOLDINGS, LLC, NEW HAMPSHIRE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CAMMARATA, MARIE;REEL/FRAME:017905/0601 Effective date: 20060710 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |